EURopean Trial In Atrial Fibrillation(AF) or Flutter (AFL) Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)
Launched by SANOFI · Nov 25, 2005
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
This is a double-blind, parallel arm, placebo-controlled, multicentre, multinational, phase III study.
To be eligible, patients must be in normal sinus rhythm at randomisation and must have an ECG-documented history of recent AF/AFL reverted to normal sinus rhythm by electrical, pharmacological or spontaneous conversion
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients of either sex aged 21 years or more, in sinus rhythm for at least 1 hour at the time of randomization and with at least one ECG-documented AF/AFL episode in the last 3 months.
- Exclusion Criteria:
- * MAIN CRITERIA (non-exhaustive list, see protocol for details):
- • Women of childbearing potential without adequate birth control, Pregnant women, Breastfeeding women, Congestive heart failure NYHA class III or IV, Conditions which increase the risk of severe antiarrhythmic drug side effects, Severe associated conditions.
About Sanofi
Sanofi is a global healthcare leader dedicated to empowering life through innovation in pharmaceuticals and vaccines. With a strong commitment to research and development, Sanofi focuses on addressing complex health challenges across various therapeutic areas, including diabetes, oncology, immunology, and rare diseases. The company leverages advanced science and technology to develop transformative therapies that improve patient outcomes. Through collaborative partnerships and a patient-centric approach, Sanofi strives to enhance global health and deliver sustainable solutions that meet the evolving needs of healthcare systems and communities worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Diegem, , Belgium
Praha, , Czech Republic
Paris, , France
Barcelona, , Spain
Horsholm, , Denmark
Helsinki, , Finland
Gouda, , Netherlands
Warszawa, , Poland
Milano, , Italy
Berlin, , Germany
Guildford, , United Kingdom
Budapest, , Hungary
Patients applied
Trial Officials
ICD Clinical study director (CSD)
Study Director
Sanofi
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials